Clinical Trials Logo

Gastric Cancer clinical trials

View clinical trials related to Gastric Cancer.

Filter by:

NCT ID: NCT02287168 Completed - Gastric Cancer Clinical Trials

Effect of Peritoneal Lavage on Surgery-induced Positive Peritoneal Cytology in Gastric Cancer Patients

Start date: October 2014
Phase: Phase 0
Study type: Interventional

Surgical manipulation and handling of a tumor may cause dissemination of cancer cells through peritoneal cavity after curative gastrectomy. Intra operative peritoneal lavage may have preventive effect on positive peritoneal cytology occurred during gastrectomy in patients with gastric cancer.

NCT ID: NCT02276300 Completed - Breast Cancer Clinical Trials

HER2-Peptide Vaccination of Patients With Solid Tumors

HER2
Start date: December 2014
Phase: Phase 1
Study type: Interventional

Investigation of peptide vaccination targeting HER2/neu in patients with metastasized breast or gastric cancer with moderate HER2/neu expression.

NCT ID: NCT02274376 Completed - Gastric Cancer Clinical Trials

Non-Interventional Study of Xeloda (Capecitabine) in Patients With Gastric Cancer

Start date: August 2008
Phase: N/A
Study type: Observational

This observational study will collect prospective data on the safety and tolerability of Xeloda in patients with advanced gastric cancer from every day clinical practice. Documentation of treatment for each patient is to continue until the end of treatment per oncologist's assessment.

NCT ID: NCT02267343 Completed - Gastric Cancer Clinical Trials

Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer

Start date: October 2014
Phase: Phase 3
Study type: Interventional

The purpose of study is to evaluate the efficacy and safety of ONO-4538 in patients with unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) refractory to or intolerant of standard therapy.

NCT ID: NCT02252913 Completed - Gastric Cancer Clinical Trials

A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer

Start date: September 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of volitinib in combination with docetaxel in patients with locally advanced or metastatic gastric cancer and to determine the Maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of volitinib in combination with docetaxel.

NCT ID: NCT02233712 Completed - Gastric Cancer Clinical Trials

Open-label, Dose-finding Study to Determine Antibody Response to G17DT Treatment in Patients With Gastric Cancer.

GC3
Start date: August 1999
Phase: Phase 2
Study type: Interventional

An open label, dose-finding, schedule-changing, sequential, multiple dose, multi-center study in patients with Stage I-III gastric cancer. The first group of patients received a starting dose of 250 µg at weeks 0, 1, and 3. Thereafter, allocation to treatment with 100 µg or 500 µg was based on antibody response and dose tolerability.

NCT ID: NCT02229058 Completed - Gastric Cancer Clinical Trials

Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer

Start date: February 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effectiveness and safety of s-1 plus Albumin Bound Paclitaxel as first-line therapy in the treatment of patients with advanced gastric cancer.

NCT ID: NCT02191761 Completed - Colorectal Cancer Clinical Trials

Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer

Start date: June 19, 2014
Phase: Phase 1
Study type: Interventional

This is an open-label, multi-center, dose escalation study in adult subjects with advanced colorectal, gastric, hepatic or pancreatic cancer. The study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of SM04755 administered orally. Upon determination of the maximum tolerated dose (MTD), expansion cohorts may be enrolled.

NCT ID: NCT02178956 Completed - Gastric Cancer Clinical Trials

A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer

BRIGHTER
Start date: October 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to find out whether it is better to receive a new drug, BBI608, in addition to paclitaxel chemotherapy or better to receive paclitaxel chemotherapy alone as second line treatment for gastric and gastroesophageal junction cancer after prior first line platinum and fluoropyrimidine based chemotherapy.

NCT ID: NCT02178722 Completed - Lung Cancer Clinical Trials

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Start date: July 17, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.